Treatment- and population-specific genetic risk factors for anti-drug antibodies against interferon-beta: a GWAS

BACKGROUND: Upon treatment with biopharmaceuticals, the immune system may produce anti-drug antibodies (ADA) that inhibit the therapy. Up to 40% of multiple sclerosis patients treated with interferon β (IFNβ) develop ADA, for which a genetic predisposition exists. Here, we present a genome-wide asso...

Descripción completa

Detalles Bibliográficos
Autores principales: Andlauer, Till F. M., Link, Jenny, Martin, Dorothea, Ryner, Malin, Hermanrud, Christina, Grummel, Verena, Auer, Michael, Hegen, Harald, Aly, Lilian, Gasperi, Christiane, Knier, Benjamin, Müller-Myhsok, Bertram, Jensen, Poul Erik Hyldgaard, Sellebjerg, Finn, Kockum, Ingrid, Olsson, Tomas, Pallardy, Marc, Spindeldreher, Sebastian, Deisenhammer, Florian, Fogdell-Hahn, Anna, Hemmer, Bernhard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7641861/
https://www.ncbi.nlm.nih.gov/pubmed/33143745
http://dx.doi.org/10.1186/s12916-020-01769-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7641861/
https://www.ncbi.nlm.nih.gov/pubmed/33143745
http://dx.doi.org/10.1186/s12916-020-01769-6

Ejemplares similares